https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-26 08:34:052026-03-26 08:34:05Hansa Biopharma publishes 2025 Annual and Sustainability Reports
https://www.optimumcomms.com/wp-content/uploads/2026/02/Laigo-website-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-23 08:50:032026-03-23 08:50:03Laigo Bio completes final close of oversubscribed seed financing of €17 million co-led by Biovance Capital and Kurma Partners to advance oncology and auto-immunity programs
https://www.optimumcomms.com/wp-content/uploads/2025/07/hansa.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-20 09:13:472026-03-20 09:13:47Hansa Biopharma announces a USD 30 million convertible note financing
https://www.optimumcomms.com/wp-content/uploads/2026/02/BOOSTPharma_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-19 11:30:522026-04-01 12:29:59BOOST Pharma Appoints Leading Biopharma Leader Elaine Jones as Chair
https://www.optimumcomms.com/wp-content/uploads/2025/12/Oncoinvent_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-19 08:38:462026-03-19 08:38:46Oncoinvent secures new patent expanding protection for Radspherin®
https://www.optimumcomms.com/wp-content/uploads/2026/01/Atrogi_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-18 08:34:592026-03-18 08:34:59Atrogi announces first subjects dosed in human trial for lead candidate ATR-258
https://www.optimumcomms.com/wp-content/uploads/2026/03/AMS_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-18 07:10:522026-03-18 07:10:52Advanced Medical Solutions Group plc: Unaudited preliminary results for the year ended 31 December 2025
https://www.optimumcomms.com/wp-content/uploads/2026/03/R1_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-17 12:28:512026-03-17 12:28:51R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease
https://www.optimumcomms.com/wp-content/uploads/2024/04/Outrun_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-17 08:35:202026-03-17 08:35:20Outrun Therapeutics unveils lead programme targeting HPV positive head and neck cancer and appoints renowned E3 ligase experts to Scientific Advisory Board (SAB)
https://www.optimumcomms.com/wp-content/uploads/2026/03/Mestag_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-17 08:17:292026-03-17 08:17:29Mestag Therapeutics Announces $40 Million Financing and Appoints Chief Medical Officer and Chief Development Officer in Preparation to Enter the Clinic
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-13 16:34:222026-03-13 16:34:22Hansa Biopharma presenting at Redeye Theme Event: Commercialization in Life Science
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-12 08:34:542026-03-12 08:35:12Poolbeg Pharma plc – Appointment of Dr Adrian Kilcoyne to Scientific Advisory Board
https://www.optimumcomms.com/wp-content/uploads/2025/03/Novo_Holdings23_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-12 08:28:432026-03-12 08:28:58Novo Holdings announces 2025 Annual Results 
https://www.optimumcomms.com/wp-content/uploads/2024/04/Template_Logo_300x180px-80x80Web_Logos-7.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-11 08:33:262026-03-11 08:33:26Commit Biologics appoints serial biotech founder as new CEO to take complement-powered immune engagers into the clinic
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-10 10:54:112026-03-10 10:54:11Hansa Biopharma participating at DNB Carnegie Healthcare Conference 2026
https://www.optimumcomms.com/wp-content/uploads/2026/01/Kainova_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-10 08:30:262026-03-10 08:30:26Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors
https://www.optimumcomms.com/wp-content/uploads/2026/01/Numares_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-09 17:32:442026-03-09 17:32:44New paper in Frontiers in Medicine reveals first reliable biomarker test for early kidney transplant rejection detection in living-donor recipients
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-09 11:01:502026-03-09 11:04:44Hansa Biopharma participating at LSX Investival Showcase USA
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-06 17:04:402026-03-06 17:08:55Hansa Biopharma participating at Leerink Global Healthcare Conference
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-05 08:43:252026-03-05 08:43:40PDUFA Action Date for Hansa Biopharma’s Imlifidase BLA Set for December 19, 2026For more information about Optimum Strategic Communications, please get in touch.
